RxDoctor Payments Data

Nigella Siegl, NP

Nurse Practitioner · Charlotte, NCNPI 1942819594

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 27 payments — averaging $46.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$257
  • Impulse Dynamics (USA) Inc.$168
  • Novartis$162
  • Edwards Lifesciences$158
  • Cvrx, Inc.$150
  • Abbott$144
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$1,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$74,764
Medicare patients
579
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban725$747,551
EntrestoSacubitril/Valsartan186$205,772
XareltoRivaroxaban105$134,436
Repatha SureclickEvolocumab130$102,922
JardianceEmpagliflozin41$35,127
FarxigaDapagliflozin Propanediol19$21,665
Praluent PenAlirocumab16$10,566
Metoprolol Succinate513$7,045
Atorvastatin Calcium590$5,471
Flecainide Acetate111$5,253
Diltiazem 24hr Er (Cd)Diltiazem Hcl177$4,768
Ranolazine ErRanolazine31$3,609
Ezetimibe207$3,460
Rosuvastatin Calcium322$3,304
Potassium Chloride121$2,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$747,551725 claims
NovartisEntresto$162$205,772186 claims
Boehringer IngelheimJardiance$14$35,12741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →